Today is #RareDiseaseDay and MERIT joins the global movement to raise awareness of rare diseases. Over 300 million people around world live with a rare disease and 72% of rare diseases are genetic. We have supported dozens of gene therapy #clinicaltrials for rare inherited retinal diseases such as Leber's Congenital Amaurosis, Retinitis Pigmentosa, and Usher Syndrome. Learn more about rare diseases: https://lnkd.in/gk6hbAF
MERIT CRO
生物技术研究
Madison，Wisconsin 4,948 位关注者
MERIT is a global clinical trial endpoint services provider offering reliable expertise in our therapeutic areas.
关于我们
MERIT is an innovative clinical endpoint expert providing attentive expertise in our therapeutic areas. We partner with CROs, pharma, and biotech companies to deliver reliable endpoint services in global clinical trials. With the acquisition of OSOD, MERIT now offers preclinical research services, enabling a seamless transition from preclinical to clinical phases of drug development. Together our work advances and accelerates the improvement of therapeutic options for patients worldwide. We have a proven track record providing endpoint expertise to 13 of the top 20 global pharmaceutical companies. We prioritize a collaborative, partnership-driven approach for all projects with scalable solutions and personalized attention. If you’re looking for a partner that will bring dedication and expertise to your clinical trial, consider MERIT.
- 网站
-
https://www.meritcro.com/?utm_source=LinkedIn&utm_medium=CompanyPage&utm_campaign=Referral
MERIT CRO的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Madison，Wisconsin
- 类型
- 私人持股
- 创立
- 2012
- 领域
- Ophthalmology clinical trials、corneal endothelial cell count、optical coherence tomography、technician and equipment certification、imaging CRO、Cloud-based imaging platform、Respiratory clinical trials、Contract Research Organization、Respiratory CRO、COPD clinical trials、Asthma clinical trials、AMD clinical trials、Oncology clinical trials、Clinical Endpoint Assessment和Preclinical Research
产品
![点击此处查看EXCELSIOR Imaging Software]()
EXCELSIOR Imaging Software
图片存档与通信系统 (PACS) 软件
MERIT’s EXCELSIOR technology platform increases accuracy and efficiency by providing a suite of advanced endpoint analysis tools designed based on our extensive collaboration with biopharma companies. With MERIT your study data and images can easily be shared between clinical sites, reading centers, CROs, and Sponsors for maximum transparency. This makes managing global trials involving multiple reading centers and analysis of numerous modalities not only feasible, but practical.
地点
MERIT CRO员工
-
Yijun Huang
CEO at MERIT CRO, Inc.
-
Laura Erker
Director of Ophthalmology Reading Center Operations at MERIT CRO Clinical trial endpoint expert
-
Julia Oxley, MBA
Accomplished business professional with extensive experience in leading business development, budgeting, contracting, and operations across multiple…
-
Laura Jacobs
Proposal Development Specialist
动态
-
What is a retrospective vs a prospective study, and what unique challenges do sites face when participating in these trials? What role do DICOM headers play in imaging? Learn the answers to these questions and more in our upcoming webinar! Register now: https://lnkd.in/gGAi-KNa Speakers: Alyssa Bartholomew, Sally Asad, MPH, CPH, and Satej Bhogill #MERITCRO #MERITCROWebinar #YourClinicalEndpointExpert #clinicaltrials #clinicalresearch #oncology #webinar
-
-
We're ready for day 2 of #AACRIO25 in Los Angeles! We invite you to stop by booth 110 this afternoon to visit with the MERIT team and pick up some fun giveaways. MERIT staff present: Dr. Fanny Wang, Satej Bhogill, Gene Kim, PharmD #MERITCRO #YourClinicalEndpointExpert #oncologytrials #oncologyresearch #clinicaltrials #clinicalresearch #oncology
-
-
OT reports on Glaukos Corporation achieving an important milestone in the NDA submission process. The FDA has acknowledged the company’s NDA for Epioxa, a corneal cross-linking treatment for keratoconus, is sufficiently complete to permit review and a PDUFA date is set for October 20, 2025. Epioxa is non-invasive, enhancing corneal strength without epithelial removal.
Glaukos has announced it has received the “Day 74” notification from the US Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa is sufficiently complete to permit a substantive review. Glaukos had originally filed the NDA with the FDA at the end of 2024. A Day 74 letter from the FDA is a key part of the NDA process, which confirms A PDUFA goal date, confirms standard versus priority review, and communicates any filing review issues identified by the FDA. A Prescription Drug User Fee Act (PDUFA) date for the completion of the FDA’s review of the Epioxa NDA has been set for October 20, 2025, reflecting a standard 10-month review period Read More: https://ow.ly/2XZn50V5jEC
FDA accepts NDA for epi-on corneal crosslinking Epoxia from Glaukos
-
MeiraGTx announced encouraging news regarding their #genetherapy treatment for AIPL1-related retinal dystrophy, LCA4, a retinal dystrophy that leaves children with only the ability to distinguish light and dark at birth. 4 out of 4 young children with LCA4 benefited from unilateral subretinal administration in the FIH trial, with improved visual acuity, functional vision, and protection against progressive retinal degeneration.
?? Gene Therapy Restores Vision in Children with Genetic Blindness ??? A groundbreaking gene therapy has given four children with AIPL1 deficiency, a severe form of retinal dystrophy, life-changing improvements in vision. Developed by UCL Institute of Ophthalmology and Moorfields Eye Hospital, with support from MeiraGTx, this treatment offers new hope for genetic blindness. ?? Key Findings: ? Healthy copies of the AIPL1 gene were delivered into retinal cells, helping them function and survive. ? All four children saw significant vision improvements in the treated eye over three to four years. ? Published in The Lancet, the study highlights how early gene therapy can transform lives. With gene therapy for RPE65 deficiency already available through the NHS, this breakthrough could pave the way for wider treatments for genetic blindness. ?? Read more here: https://lnkd.in/dUathC98 #GeneTherapy #VisionLoss #ScientificResearch #Innovation #Ophthalmology
Gene Therapy Restores Vision in Children
ophthalmologybreakingnews.com
-
We asked which oncology conference you're most excited to attend. The results showed almost half of respondents prioritize the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. #ASCO25 in the windy city will be a great conference, and we hope to see you there! MERIT's oncology experts will be at all of these shows. Message Satej Bhogill or Christopher Sylvia to schedule a personalized planning session with our team! American Society of Clinical Oncology (ASCO) Annual Meeting - booth 32157 American Association for Cancer Research (AACR) Annual Meeting - booth 3744 Immuno-Oncology 360 Summit - booth 35 AACR Immuno-Oncology (IO) - booth 110 #AACRIO25 #IO360Summit #AACR25 #AACR2025 #MERITCRO #YourClinicalEndpointExpert #oncologyresearch #oncologytrials #endpointsolutions
-
-
Time flies when you’re having fun! Hard to believe it’s been over 12 years since EyeKor (now MERIT) was founded. Then and now with our CEO, Dr. Yijun Huang, and VP of Product Development, Nathan Diers.??
-
-
We're in route to #AACRIO25 in Los Angeles! The exhibit hall opens on Monday - we invite you to visit us at booth 110. See you soon! https://lnkd.in/gweQa-_a MERIT staff attending: Fanny Wang, Gene Kim, PharmD, Satej Bhogill #MERITCRO #YourClinicalEndpointExpert #oncologytrials #oncologyresearch #clinicaltrials #clinicalresearch #oncology
-
-
MERIT is a premier endpoint expert with a global presence. We serve as the trusted core-lab partner to our clients and provide?clinical knowledge,?technical know-how, and?operational?and?regulatory excellence?in our shared journey of developing new therapeutics and treatments.?With the acquisition of?OSOD, MERIT now offers preclinical research services, enabling a seamless transition from preclinical to clinical phases of drug development. Learn more: https://lnkd.in/gm_ACnTc #MERITCRO #YourClinicalEndpointExpert #clinicaltrials #clinicalresearch #preclinicalresearch OSOD, Ocular Services On Demand
-